Abstract 200P
Background
Malignant Mixed Mullerian Tumor (MMMT) also known as carcinosarcoma is considered as a rare aggressive biphasic tumor with carcinomatous and sarcomatous elements found in postmenopausal women, uterus being the most common site, followed by cervix, vagina, and rarely adnexa or vulva. It usually presents at an advanced stage and lacks specific treatment guidelines requiring a multimodality approach with surgery and chemoradiation (CTRT) for better prognosis & outcomes. The aim was to study the patterns of failure and overall survival in patients treated with different modalities.
Methods
An observational analysis of 82 patients from the year 2015-2019 was done including demographic data such as age and ECOG status. The patients were staged based on the FIGO 2019 system after imaging and histopathological examination. The different treatment regimens with surgery and lymph node dissection (LND), CTRT used as definitive or adjuvant therapy was noted. This study shows the impact of surgery and CTRT on overall survival (OS), progression free survival (PFS) and disease specific survival (DSS) according to stage and type of treatment. We conducted Kaplan-Meier method with log-rank tests for comparison of prognostic factors with survival and Cox proportional hazard model for both univariate and multivariate analysis considering p values <0.05 to be statistically significant. The median follow-up period was 35 months (4-76).
Results
The OS rate was 37.8% with a median of 28 months (95% CI: 22.3-33.6), a better OS was present by 34 months (95% CI: 17.18-50.81) in patients who had received adjuvant CTRT, 12 months (95% CI: 9-15) with definitive CTRT, while 7 months (95% CI: 4-10) with only surgery. There was a statistically significant improvement (p-0.001) in overall survival rate by 65.5% for those who underwent both LND with radiation. The PFS rate was 58.5% with a median of 47 months; stage I-IIIC with both surgery and CTRT had a better PFS and DSS by 64.3% and 46.4% respectively (p-0.001).
Conclusions
Patients receiving stagewise combined modality approach with both surgery and CTRT for management had a significantly better OS, PFS and DSS in comparison to with only single mode of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract